Quick Answer
Ovid Therapeutics Inc. reported Total Revenue of $7.25 million for fiscal year 2025.
Ovid Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $7.25M +1181.3% |
$566.0K +44.4% |
$392.0K -73.9% |
$1.50M -99.3% |
$208.38M | — |
| Revenue (ASC 606) | $7.25M +1181.3% |
$566.0K +44.4% |
$392.0K -73.9% |
$1.50M -99.3% |
$208.38M | — |
| Net Income | -$17.41M +34.1% |
-$26.43M +49.5% |
-$52.34M +3.4% |
-$54.17M -144.1% |
$122.83M +251.6% |
-$81.04M -34.0% |
| Diluted EPS | — | — | -$0.74 +3.9% |
-$0.77 -143.8% |
$1.76 +226.6% |
-$1.39 |
| Total Assets | $150.93M +63.8% |
$92.17M -36.0% |
$144.03M -7.2% |
$155.27M -20.2% |
$194.54M +156.2% |
$75.93M -6.1% |
| Cash and Equivalents | $13.15M -50.0% |
$26.30M -2.7% |
$27.04M -39.7% |
$44.87M -76.1% |
$187.80M +160.7% |
$72.03M +71.9% |
| Stockholders Equity | $130.66M +91.5% |
$68.23M -22.3% |
$87.80M -33.6% |
$132.27M -26.4% |
$179.75M +312.0% |
$43.63M -37.7% |
| R&D Expense | $25.58M -30.4% |
$36.77M +28.6% |
$28.59M +16.1% |
$24.62M -47.6% |
$46.94M -26.0% |
$63.42M +50.4% |
| Operating Income | -$42.44M +31.4% |
-$61.88M -4.4% |
-$59.28M -6.7% |
-$55.55M -144.7% |
$124.21M +252.5% |
-$81.43M -32.6% |
| Shares Outstanding | 130.18M +83.3% |
71.01M +0.4% |
70.69M +0.3% |
70.47M +0.1% |
70.36M +7.0% |
65.74M +20.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $132.0K | -23.7% | -97.9% |
| Revenue (ASC 606) | September 30, 2025 | $132.0K | -23.7% | -97.9% |
| Net Income | September 30, 2025 | -$12.16M | +13.2% | -159.6% |
| Diluted EPS | September 30, 2024 | -$0.20 | -25.0% | -266.7% |
| Total Assets | September 30, 2025 | $63.85M | -37.8% | -17.5% |
| Cash and Equivalents | September 30, 2025 | $20.61M | +37.3% | -27.5% |
| Stockholders Equity | September 30, 2025 | $44.70M | -41.4% | -19.9% |
| R&D Expense | September 30, 2025 | $5.87M | -25.3% | -9.2% |
| Operating Income | September 30, 2025 | -$12.52M | +5.3% | -146.9% |
| Shares Outstanding | September 30, 2025 | 71.15M | +0.2% | +0.1% |
- Ovid Therapeutics Inc. reported Total Revenue of $7.25 million for fiscal year 2025.
- Ovid Therapeutics Inc. showed an increase of +1181.3% in Total Revenue compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported Revenue (ASC 606) of $7.25 million for fiscal year 2025.
- Ovid Therapeutics Inc. showed an increase of +1181.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported Net Income of -$17.41 million for fiscal year 2025.
- Ovid Therapeutics Inc. showed an increase of +34.1% in Net Income compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported Diluted EPS of $0.74 per share (loss) for fiscal year 2023.
- Ovid Therapeutics Inc. showed an increase of +3.9% in Diluted EPS compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported Total Assets of $150.93 million for fiscal year 2025.
- Ovid Therapeutics Inc. showed an increase of +63.8% in Total Assets compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported Cash and Equivalents of $13.15 million for fiscal year 2025.
- Ovid Therapeutics Inc. showed a decrease of -50.0% in Cash and Equivalents compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported Stockholders Equity of $130.66 million for fiscal year 2025.
- Ovid Therapeutics Inc. showed an increase of +91.5% in Stockholders Equity compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported R&D Expense of $25.58 million for fiscal year 2025.
- Ovid Therapeutics Inc. showed a decrease of -30.4% in R&D Expense compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported Operating Income of -$42.44 million for fiscal year 2025.
- Ovid Therapeutics Inc. showed an increase of +31.4% in Operating Income compared to the prior fiscal year.
- Ovid Therapeutics Inc. reported Shares Outstanding of 130.18 million shares for fiscal year 2025.
- Ovid Therapeutics Inc. showed an increase of +83.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: